Onyx Pharmaceuticals Inc (ONXX.O)

ONXX.O

About

Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	1.13
Market Cap (Mil.):	$6,758.11
Shares Outstanding (Mil.):	72.74
Dividend:	--
Yield (%):	--

Financials

	ONXX.O	Industry	Sector
P/E (TTM):	--	53.09	35.13
EPS (TTM):	-2.51	--	--
ROI:	-11.63	0.99	18.83
ROE:	-17.03	1.98	19.68

Latest News about ONXX.O

FUNDVIEW-Healthcare M&A to gain pace in 2013 - OrbiMed's Isaly

Feb 7 - Healthcare deals will rebound this year after a weak 2012, with providers of innovative technologies, cancer treatments and diagnostics being the most likely targets, the founder and managing partner of healthcare-focused OrbiMed Advisors said.

07 Feb 2013

Onyx to test cancer drug for wider use

- Onyx Pharmaceuticals Inc said it was planning to test its approved blood cancer drug Kyprolis in patients with newly diagnosed multiple myeloma.

07 Jan 2013

» More ONXX.O News

Competitors

	Price	Change
Takeda Pharmaceutical Company Limited (4502.T)	¥4,965	+20.00
Astellas Pharma Inc (4503.T)	¥5,780	+90.00
Pfizer Inc. (PFE.N)	$29.30	+0.52
Novartis AG (NOVN.VX)	CHF73.65	+1.25
Merck & Co., Inc. (MRK.N)	$46.71	-0.62
Roche Holding Ltd. (ROG.VX)	CHF258.50	+7.50
Bayer AG (BAYGn.DE)	€85.50	+0.85
Bayer AG (BAYE.F)	--	--
AstraZeneca plc (AZN.L)	3,485.50p	+91.00
GlaxoSmithKline plc (GSK.L)	1,773.00p	+31.00

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - ONYX PHARMACEUTICALS, INC. (ONXX-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
Trading Report for (ONXX). A detailed report, including free correlated market analysis, and updates. Provider: Stock Traders Daily	$58.00 Buy
The Investment Rate - a measure of investment demand. Provider: Stock Traders Daily	$495.00 Buy
Market Edge Equity Research Report Provider: Market Edge	$10.00 Buy
ONYX Pharmaceuticals Provider: S&P Capital IQ – STARS Reports	$115.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.